1:1 FREE Shares Incoming: NATCO Pharma Demerger Approved; Here's What Investors May Get

NATCO pharma announced a major corporate restructuring move, approving a 1:1 demerger of its agrochemicals business. The decision was cleared by the company's board on March 24, to shift the focus on its core pharmaceutical segment.

As part of the plan, NATCO Pharma will spin off its agro division into a separate entity, NATCO Crop Health Sciences Ltd, a wholly-owned subsidiary. The appointed date for the demerger has been fixed as October 1, 2026, subject to necessary approvals under the Companies Act, 2013.

1:1 Demerger Explained: What Shareholders Will Get

The biggest takeaway for investors holding this Pharma stock is the 1:1 share entitlement. Existing shareholders of NATCO pharma shares will receive one share of the new agrochemical company for every one share held, ensuring that their ownership remains unchanged across both entities. This type of demerger stock news is often seen as a positive trigger, as it allows investors to benefit from separate valuation of businesses.

Why NATCO Pharma Is Splitting Its Business

The agrochemicals segment contributes only about 4% of the company's total revenue, approximately Rs.28.5 crore in Q3FY26, making it a relatively small part of the overall business.

With this NATCO pharma demerger, the company expects to strengthen its focus on high-growth pharmaceutical business and give the agro division more operational flexibility and independence. The demerger will also let both the companies have separate branding and growth strategies. Along with all that provide value for shareholders.

The company may also retain a minority stake in the new entity and continue offering support through shared services like R&D during the transition phase.

NATCO Pharma Share Price in Focus

After the announcement, Natco pharma share price saw a positive reaction. The stock on Wednesday trade closed at Rs.971.05, rising 2.24% in the latest session.

On a broader trend, NATCO Pharma stock has given solid returns, gaining 15.29% in the last six months and 17.72% over the past one year.

Geojit Equity Research in its report dated 18th March Gave a ACCUMULATE rating to the stock projecting a 12% upside from the current market price.

The report mentioned, "We revise our rating to Accumulate, with a target price of Rs.1,058, based on 21x FY28E EPS."

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.